Abbott (NYSE:ABT) said today that it inked a non-exclusive deal to integrate insulin dose data from Novo Nordisk‘s (NYSE:NVO) pre-filled and connected pens with its FreeStyle Libre mobile app and cloud-based system.
The companies touted that integrating the products will allow healthcare professionals, caregivers and users to easily view glucose and insulin data, as well as make more informed treatment decisions.
Neither Abbott nor Novo Nordisk disclosed when this feature would be available for users. Instead, they said that they are “working hard to bring these integrated solutions to patients as soon as possible.”
“Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors,” Anders Dyhr Toft, corporate VP of commercial innovation at Novo Nordisk, said in prepared remarks. “Together with partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient′s individual diabetes management and can help people with diabetes feel more confident in their treatment.”
“It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes,” Jared Watkin, SVP of Abbott’s diabetes care division, added.
“Diabetes is a time intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake. By enabling insulin dosing data from Novo Nordisk′s connected pens to be shared with our digital health tools, we′ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life,” Watkin said.
In November last year, Abbott won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system.
The FreeStyle LibreLink app allows users to capture and view their glucose data in real-time using their mobile phones. Prior to the mobile app, people using Abbott’s FreeStyle Libre CGM had to use a separate device to connect data from the sensor to their phones.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.